FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cook Timothy DeVere
2. Issuer Name and Ticker or Trading Symbol

Athenex, Inc. [ ATNX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600
3. Date of Earliest Transaction (MM/DD/YYYY)

7/15/2022
(Street)

BUFFALO, NY 14203
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 7/15/2022  A  843 (1)A$0.5935 8133 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $17.29            (2)8/16/2028 Common Stock 70000  70000 D  
Stock Option (Right to Buy) $10.26            (3)8/27/2030 Common Stock 30000  30000 D  
Stock Option (Right to Buy) $3.56            (4)9/16/2031 Common Stock 9000  9000 D  
Restricted Stock Units  (5)           (6) (6)Common Stock 9000  9000 D  

Explanation of Responses:
(1) Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
(2) This option vests in four equal annual installments beginning on August 16, 2019.
(3) This option vests in four equal annual installments beginning on August 27, 2021.
(4) This option vests in four equal annual installments beginning on September 16, 2022.
(5) Each restricted stock unit represents a contingent right to receive one share of stock.
(6) The restricted stock units vest in four equal annual installments beginning on September 16, 2022.

Remarks:
Chief Business and Commercial Officer, Proprietary Drugs

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Cook Timothy DeVere
C/O ATHENEX, INC., 1001 MAIN STREET
SUITE 600
BUFFALO, NY 14203


See Remarks

Signatures
/s/Steven Adams, Attorney-in-Fact7/18/2022
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Athenex Charts.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Athenex Charts.